USA-based development stage company TG Therapeutics (Nasdaq: TGTX) achieved positive results from the Phase IIb UNITY-NHL study using umbralisib in patients with marginal zone lymphoma (MZL), setting the scene for potential accelerated approval.
The announcement on Friday saw TG Therapeutics’ shares close up 4.93% at $6.38 and up further in after-hours trading to $6.44.
TG Therapeutics announced the successful outcome of meetings held by the independent Data Safety Monitoring Boards (DSMBs) for both the UNITY-CLL trial and for the UNITY-NHL trial with umbralisib, which was granted Breakthrough Therapy designation in the USA in January this year for the treatment of MZL.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze